Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's Disease: A retrospective cohort study.

Saved in:
Bibliographic Details
Title: Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie's Disease: A retrospective cohort study.
Authors: Durukan E; Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark. emil.durukan.01@regionh.dk., Kraglund R; Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark., Rashid SA; Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark., Thorkilgaard T; Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark., Jensen CFS; Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark., Fode M; Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Source: International journal of impotence research [Int J Impot Res] 2024 Apr; Vol. 36 (2), pp. 151-154. Date of Electronic Publication: 2024 Jan 16.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9007383 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5489 (Electronic) Linking ISSN: 09559930 NLM ISO Abbreviation: Int J Impot Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5489
DOI:10.1038/s41443-023-00810-5